| Literature DB >> 32214921 |
Chun-Lei Cheng1, Xian-Hui Jia2,3,4, Cheng-Mei Xiao2,3,4, Wen-Zhao Tang2,3,4.
Abstract
Paulownia species, especially their flowers and fruits, are traditionally used in Chinese herbal medicines for the treatment of infectious diseases. C-geranylated flavonoids were found to be the major special metabolites in Paulownia flowers and fruits, and 76 C-geranylated flavonoids had been isolated and characterized thus far. Structural variations in Paulownia C-geranylated flavonoids are mainly due to the complicated structural modifications in their geranyl substituents. These natural compounds have attracted much attention because of their various biological activities, including antioxidation, anti-inflammation, cytotoxic activity and various enzymatic inhibitions, etc. Among them, diplacone, a major Paulownia component, was considered to have promise for applications in medicine. This paper summarizes the information from current publications on Paulownia C-geranylated flavonoids, with a focus on their structural variety, key spectroscopic characteristics, biological activity with structure-activity relationships and application prospects. We hope that this paper will stimulate further investigations of Paulownia species and this kind of natural product. © Springer Nature B.V. 2019.Entities:
Keywords: Biological properties; C-geranylated flavonoids; Paulownia species; Phytochemistry
Year: 2019 PMID: 32214921 PMCID: PMC7088933 DOI: 10.1007/s11101-019-09614-2
Source DB: PubMed Journal: Phytochem Rev ISSN: 1568-7767 Impact factor: 5.374
Fig. 1Structural skeleton of C-geranylated flavonoids obtained from Paulownia species
Paulownia plants in China
| No. | Chinese name | Plant Latin name |
|---|---|---|
| 1 | 楸叶泡桐 | |
| 2 | 兰考泡桐 | |
| 3 | 川泡桐 | |
| 4 | 白花泡桐 | |
| 5 | 台湾泡桐 | |
| 6 | 毛泡桐 | |
| 7 | 南方泡桐 | |
| 8 | 毛泡桐(原变种) | |
| 9 | 光泡桐 | |
| 10 |
The plant Latin names are presented according to the new classification (http://www.theplantlist.org), even though older classifications are presented in the references
aStatus as “Synonym”
bThe Paulownia species, Paulownia coreana Uyeki, investigated by Jin et al. is an unresolved name and is not accepted in Flora of China (1998) by the Chinese Flora Editorial Committee
Fig. 2Unmodified C-geranylflavanones isolated from the Paulownia genus
Fig. 3Noncyclic modified C-geranylflavanones isolated from the Paulownia genus
Fig. 4Cyclic modified C-geranylflavanones isolated from the Paulownia genus
Fig. 5Degraded C-geranylflavanones isolated from the Paulownia genus
Fig. 6C-geranylated flavones isolated from the Paulownia genus
The distribution of C-geranylated flavonoids in Paulownia species
| Compounds | Name | Species | Part | References |
|---|---|---|---|---|
|
| Mimulone |
| Fruit | Navrátilová et al. ( |
| Cho et al. ( | ||||
| Hanáková et al. ( | ||||
| Flower | Chen et al. ( | |||
| Jiang et al. ( | ||||
|
| Flower | Duan et al. ( | ||
| Leaf | Li et al. ( | |||
|
| Diplacone |
| Fruit secretion | Asai et al. ( |
| Fruit | Navrátilová et al. ( | |||
| Cho et al. ( | ||||
| Ryu et al. ( | ||||
| Flower | Chen et al. ( | |||
| Jiang et al. ( | ||||
|
| Flower | Duan et al. ( | ||
|
| Fruit | Wang et al. ( | ||
|
| Flower | Jin et al. ( | ||
|
| Schizolaenone C |
| Fruit | Šmejkal et al. ( |
|
| 3′- |
| Fruit secretion | Asai et al. ( |
| Fruit | Šmejkal et al. ( | |||
| Cho et al. ( | ||||
| Hanáková et al. ( | ||||
| Ryu et al. ( | ||||
|
| Flower | Duan et al. ( | ||
|
| 3′- |
| Fruit | Šmejkal et al. ( |
|
| Flower | Jin et al. ( | ||
|
| 3′-O-methyl-5′-O-methyldiplacone |
| Fruit | Šmejkal et al. ( |
|
| 4′-O-methyldiplacone |
| Fruit secretion | Asai et al. ( |
| Fruit | Cho et al. ( | |||
|
| 3′,4′- |
| Fruit | Hanáková et al. ( |
|
| 6-Geranyl-5,7,3′,5′-tetrahydroxy-4′-methoxyflavanone |
| Fruit | Ryu et al. ( |
|
| 6-Geranyl-5,7-dihydroxy-3′,4′-dimethoxyflavanone |
| Fruit secretion | Asai et al. ( |
| Fruit | Hanáková et al. ( | |||
|
| 6-Geranyl-4′,5,7-trihydroxy-3′,5′-dimethoxyflavanone |
| Fruit secretion | Asai et al. ( |
| Fruit | Navrátilová et al. ( | |||
| Cho et al. ( | ||||
| Hanáková et al. ( | ||||
| Ryu et al. ( | ||||
|
| Flower | Jin et al. ( | ||
|
| 6-Geranyl-4′,5,5′,7-tetrahydroxy-3′-methoxyflavanone |
| Fruit secretion | Asai et al. ( |
| Fruit | Navrátilová et al. ( | |||
|
| 6-Geranyl-3,3′,5,7-tetrahydroxy-4′-methoxyflavanone (4′- |
| Fruit secretion | Asai et al. ( |
| Fruit | Cho et al. ( | |||
| Ryu et al. ( | ||||
|
| Flower | Zhang and Li ( | ||
|
| Diplacol |
| Fruit secretion | Asai et al. ( |
|
| Flower | Jin et al. ( | ||
|
| 3′- |
| Fruit secretion | Asai et al. ( |
| Flower | Kobayashi et al. ( | |||
| Fruit | Navrátilová et al. ( | |||
| Cho et al. ( | ||||
| Hanáková et al. ( | ||||
| Šmejkal et al. ( | ||||
|
| Flower | Zhang and Li ( | ||
|
| Flower | Jin et al. ( | ||
|
| 6-Geranyl-3,3′,5,5′,7-pentahydroxy-4′-methoxyflavane |
| Fruit | Cho et al. ( |
|
| 3′- |
| Fruit | Šmejkal et al. ( |
|
| 3′- |
| Flower | Jin et al. ( |
|
| Paucatalinone A |
| Fruit | Gao et al. ( |
|
| 5,7-Dihydroxy-6-(7-hydroxy-3,7-dimethyloct-2-en-1-yl)-2S-(4-hydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one |
| Fruit | Ryu et al. ( |
|
| Fruit peel | Wang et al. ( | ||
|
| Prokinawan |
| Flower | Kobayashi et al. ( |
| Fruit secretion | Asai et al. ( | |||
| Fruit | Ryu et al. ( | |||
|
| Fruit | Tang et al. ( | ||
|
| 3,3′,4′,5,7-Pentahydroxy-6-[7-hydroxy-3,7-dimethyl-2( |
| Fruit secretion | Asai et al. ( |
|
| Tomentin J |
| Fruit | Ryu et al. ( |
|
| Paucatalinone J |
| Fruit | Wang et al. ( |
|
| Isopaucatalinone B |
| Fruit | Gao et al. ( |
|
| Fruit | Ryu et al. ( | ||
|
| Tomentin K |
| Fruit | Ryu et al. ( |
|
| Fruit peel | Wang et al. ( | ||
|
| Paucatalinone B |
| Fruit | Gao et al. ( |
|
| Mimulone B |
| Fruit | Schneiderová et al. ( |
|
| Flower | Jin et al. ( | ||
|
| Tomentomimulol |
| Fruit | Schneiderová et al. ( |
|
| Tanariflavanone D |
| Fruit secretion | Asai et al. ( |
| Fruit | Schneiderová et al. ( | |||
| Ryu et al. ( | ||||
|
| Tanariflavanone |
| Fruit secretion | Asai et al. ( |
|
| ( |
| Fruit secretion | Asai et al. ( |
|
| Tomentodiplacone |
| Fruit | Šmejkal et al. ( |
|
| ( |
| Fruit secretion | Asai et al. ( |
|
| Fruit peel | Wang et al. ( | ||
|
| Tomentin I |
| Fruit | Ryu et al. ( |
|
| Tomentodiplacol |
| Fruit | Šmejkal et al. ( |
|
| Paucatalinone I |
| Fruit peel | Wang et al. ( |
|
| Mimulone H |
| Fruit | Hanáková et al. ( |
|
| Tomentodiplacone M |
| Fruit | Hanáková et al. ( |
|
| Tomentodiplacone B |
| Fruit | Navrátilová et al. ( |
| Hanáková et al. ( | ||||
|
| Tomentodiplacone I |
| Fruit | Navrátilová et al. ( |
|
| Mimulone F |
| Fruit | Hanáková et al. ( |
|
| Paulownione A |
| Fruit | Hanáková et al. ( |
|
| Mimulone G |
| Fruit | Hanáková et al. ( |
|
| Tomentodiplacone G |
| Fruit | Navrátilová et al. ( |
| Hanáková et al. ( | ||||
|
| Paulownione B |
| Fruit | Hanáková et al. ( |
|
| Tomentin A |
| Fruit | Cho et al. ( |
| Ryu et al. ( | ||||
|
| Tomentin B |
| Fruit | Cho et al. ( |
|
| Ryu et al. ( | |||
| Wang et al. ( | ||||
|
| Tomentin C |
| Fruit | Cho et al. ( |
|
| Wang et al. ( | |||
|
| Tomentin D |
| Fruit | Cho et al. ( |
| Ryu et al. ( | ||||
|
| Wang et al. ( | |||
|
| Tomentin E |
| Fruit | Cho et al. ( |
| Ryu et al. ( | ||||
|
| Wang et al. ( | |||
|
| Tomentin F |
| Fruit | Ryu et al. ( |
|
| Tomentin G |
| Fruit | Ryu et al. ( |
|
| Tomentin H |
| Fruit | Ryu et al. ( |
|
| Fruit peel | Wang et al. ( | ||
|
| Paucatalinone G |
| Fruit peel | Wang et al. ( |
|
| Tomentodiplacone N |
| Fruit | Hanáková et al. ( |
|
| Tomentone |
| Fruit | Hanáková et al. ( |
|
| Tomentodiplacol B |
| Fruit | Hanáková et al. ( |
|
| Tomentodiplacone O |
| Fruit | Hanáková et al. ( |
|
| Paulownione C |
| Fruit | Hanáková et al. ( |
|
| Mimulone C |
| Fruit | Navrátilová et al. ( |
|
| Mimulone D |
| Fruit | Navrátilová et al. ( |
|
| Bonannione B |
| Fruit | Hanáková et al. ( |
|
| Tomentodiplacone L |
| Fruit | Hanáková et al. ( |
|
| Tomentodiplacone H |
| Fruit | Navrátilová et al. ( |
|
| Paucatalinone H |
| Fruit peel | Wang et al. ( |
|
| Paucatalinone F |
| Fruit peel | Wang et al. ( |
|
| Tomentodiplacone C |
| Fruit | Navrátilová et al. ( |
|
| Tomentodiplacone D |
| Fruit | Navrátilová et al. ( |
|
| Tomentodiplacone E |
| Fruit | Navrátilová et al. ( |
|
| Tomentodiplacone F |
| Fruit | Navrátilová et al. ( |
|
| Mimulone E |
| Fruit | Navrátilová et al. ( |
|
| Paucatalinone C |
| Fruit | Wang et al. ( |
|
| Paucatalinone D |
| Fruit | Wang et al. ( |
|
| Paucatalinone E |
| Fruit | Wang et al. ( |
|
| Paucatalinone K |
| Fruit peel | Wang et al. ( |
Fig. 7UV spectra for C-geranylated flavanone and C-geranylated flavone. The UV spectra of C-geranylated flavanone and C-geranylated flavone could be described by diplacone (2) and paucatalinone C (73) as samples, respectively. a UV spectrum of diplacone (2) as a C-geranylated flavanone with a main maximum absorption at approximately λ 290 nm, a shoulder peak at approximately λ 230 nm and a weak absorption at approximately λ 340 nm. b UV spectrum of paucatalinone C (73) as a C-geranylated flavone with two main maximum UV absorption at approximately λ 270 nm and λ 350 nm
Fig. 8Typical CD spectrum of 2S configurational isomer and racemic mixtures of 2R and 2S enantiomers. The typical CD spectrum of 2S configurational isomer and racemic mixtures of 2R and 2S enantiomers could be described by paucatalinone H (66) and paucatalinone F (67) as samples, respectively. a CD spectrum of paucatalinone H (66) as a 2S configurational isomer with a positive Cotton effect at approximately 328 nm and a negative effect at approximately 285 nm. b CD spectrum of paucatalinone F (67) as a racemic mixtures of 2R and 2S enantiomers with no obvious Cotton effects
Fig. 9Key ESI–MS/MS characteristics of Paulownia C-geranylated flavonoids in positive ion mode and negative ion mode. Key ESI–MS/MS characteristics of Paulownia C-geranylated flavonoids could be described with diplacone (2) as an example. a: Main ESI–MS/MS characteristics of 2 in the positive ion mode. m/z 425.1 is the quasi-molecular ion peak as [M + H]+, and m/z 300.8 is the fragment ion peak of the parent flavonoid structure with a methylene, which was produced by a neutral loss of a C9 unit from the C10 side chain in 2 by further fragmentation. b: Main ESI–MS/MS characteristics of 2 in the negative ion mode. m/z 423.0 is the quasi-molecular ion peak as [M–H]−, and m/z 285.7 is the fragment ion peak of the parent flavonoid structure, which was produced by the neutral loss of the whole C10 side chain in 2 by further fragmentation
Antioxidant activity of different Paulownia C-geranylated flavonoids in comparison to standard antioxidants
| Compounds | DPPHquenchingactivity | Cytoprotective effect (cell viability % at 10 µM) | Activity of the positive control | References |
|---|---|---|---|---|
|
| TEAC 0.4 ± 0.004 at 10 µMa | NPb | Šmejkal et al. ( | |
| TEAC 0.02 ± 0.01 at 50 µM | NP | Zima et al. ( | ||
|
| TEAC 5.2 ± 0.001 at 10 µM | NP | Šmejkal et al. ( | |
| TEAC 1.06 ± 0.04 at 50 µM | NP | Zima et al. ( | ||
| SC50 3.2 µg/mLc | α-Tocopherol (SC50 4.7 µg/mL) | Asai et al. ( | ||
| HUVECs (72.7%)e | NP | Wang et al. ( | ||
|
| TEAC 0.8 ± 0.006 at 10 µM | NP | Šmejkal et al. ( | |
| TEAC 0.12 ± 0.02 at 50 µM | NP | Zima et al. ( | ||
| SC50 3.2 µg/mL | α-Tocopherol (SC50 4.7 µg/mL) | Asai et al. ( | ||
|
| TEAC 0.98 ± 0.03 at 50 µM | NP | Zima et al. ( | |
|
| TEAC 0.29 ± 0.02 at 50 µM | NP | Zima et al. ( | |
|
| SC50 > 50 µg/mL | α-Tocopherol (SC50 4.7 µg/mL) | Asai et al. ( | |
|
| SC50 > 50 µg/mL | α-Tocopherol (SC50 4.7 µg/mL) | Asai et al. ( | |
|
| SC50 4.5 µg/mL | α-Tocopherol (SC50 4.7 µg/mL) | Asai et al. ( | |
|
| SC50 1.9 µg/mL | α-Tocopherol (SC50 4.7 µg/mL) | Asai et al. ( | |
|
| TEAC 0.10 ± 0.00 at 50 µM | NP | Zima et al. ( | |
|
| HUVECs (56.8%) | NP | Wang et al. ( | |
|
| SC50 1.9 µg/mL | α-Tocopherol (SC50 4.7 µg/mL) | Asai et al. ( | |
|
| SC50 1.8 µg/mL | α-Tocopherol (SC50 4.7 µg/mL) | Asai et al. ( | |
|
| HUVECs (56.9%) | NP | Wang et al. ( | |
|
| HUVECs (69.1%) | NP | Wang et al. ( | |
|
| HUVECs (70.0%) | NP | Wang et al. ( | |
|
| SC50 2.9 µg/mL | α-Tocopherol (SC50 4.7 µg/mL) | Asai et al. ( | |
|
| TEAC 0.14 ± 0.04 at 50 µM | NP | Zima et al. ( | |
|
| SC50 1.8 µg/mL | α-Tocopherol (SC50 4.7 µg/mL) | Asai et al. ( | |
| HUVECs (80.6%) | NP | Wang et al. ( | ||
|
| TEAC 2.0 ± 0.007 at 10 µM | NP | Šmejkal et al. ( | |
|
| HUVECs (70.3%) | NP | Wang et al. ( | |
|
| TEAC 0.12 ± 0.00at 50 µM | NP | Zima et al. ( | |
|
| HUVECs (55.4%) | NP | Wang et al. ( | |
|
| HUVECs (56.1%) | NP | Wang et al. ( | |
|
| HUVECs (69.6%) | NP | Wang et al. ( | |
|
| HUVECs (59.1%) | NP | Wang et al. ( | |
|
| HUVECs (78.4%) | NP | Wang et al. ( | |
|
| IC50 4.82 µMd | α-Tocopherol (IC50 12.11 µM) | Wang et al. ( | |
| 2BS cells (83.26%)f | α-Tocopherol (74.55%) | Wang et al. ( | ||
|
| IC50 5.15 µM | α-Tocopherol (IC50 12.11 µM) | Wang et al. ( | |
| 2BS cells (61.04%) | α-Tocopherol (74.55%) | Wang et al. ( | ||
|
| IC50 15.22 µM | α-Tocopherol (IC50 12.11 µM) | Wang et al. ( | |
| 2BS cells (58.13%) | α-Tocopherol (74.55%) | Wang et al. ( | ||
|
| HUVECs (58.2%) | NP | Wang et al. ( |
aTEAC: Trolox equivalent antioxidant capacity
bNP: data are not provided
cEC50: half maximal effective concentration
dIC50: inhibitory concentration
eHUVECs: human umbilical vein endothelial cells
f2BS cells: senescent human embryonic lung diploid fibroblasts cells
Anti-inflammatory effects of different Paulownia C-geranylated flavonoids in comparison to the positive controls
| Compounds | Anti-inflammatory effectsa,b | Positive control | References |
|---|---|---|---|
|
| Colitismodel induced in Wistar rats (ameliorated the symptoms of colitis; reduced the levels of COX-2; increased the ratio of pro-MMP2/MMP2) | Sulfasalazine | Vochyánová et al. ( |
|
| Colitismodel induced in Wistar rats (ameliorated the symptoms of colitis; reduced the levels of COX-2; increased the ratio of pro-MMP2/MMP2) | Sulfasalazine | Vochyánová et al. ( |
| cLPS-induced NO production in RAW264.7 cells (IC50 5.02 µM) | Aminoguanidine (IC50 16.60 µM) | Jin et al. ( | |
| LPS-induced murine macrophage cell lineJ774.A1 (ROS level; IκB-α degradation; COX-2 expression) | NP | Hošek et al. ( | |
| LPS-induced THP-1 cells (TNF-α expression; MCP-1 expression; ZFP36 expression) | Indomethacin | Hošek et al. ( | |
| LPS-induced THP-1 cells (TNF-α expression; nuclear translocation of NF-κB; generation of ROS) | Prednisone | Hanáková et al. ( | |
|
| LPS-induced THP-1 cells (TNF-α expression; nuclear translocation of NF-κB; generation of ROS) | Prednisone | Hanáková et al. ( |
|
| LPS-induced NO production in RAW264.7 cells (IC50 1.48 µM) | Aminoguanidine (IC50 16.60 µM) | Jin et al. ( |
|
| LPS-induced NO production in RAW264.7 cells (IC50 6.44 µM) | Aminoguanidine (IC50 16.60 µM) | Jin et al. ( |
|
| LPS-induced NO production in RAW264.7 cells (IC50 4.53 µM) | Aminoguanidine (IC50 16.60 µM) | Jin et al. ( |
|
| LPS-induced NO production in RAW264.7 cells (IC50 5.94 µM) | Aminoguanidine (IC50 16.60 µM) | Jin et al. ( |
|
| LPS-induced NO production in RAW264.7 cells (IC50 16.66 µM) | Aminoguanidine (IC50 16.60 µM) | Jin et al. ( |
|
| TNF-α-stimulated A549 cells (IL-8 expression) | NP | Ryu et al. ( |
|
| TNF-α-stimulated A549 cells (IL-8 expression) | NP | Ryu et al. ( |
|
| LPS-induced NO production in RAW264.7 cells (IC50 23.49 µM) | Aminoguanidine (IC50 16.60 µM) | Jin et al. ( |
|
| TNF-α-stimulated A549 cells (IL-8 expression) | NP | Ryu et al. ( |
|
| LPS-induced THP-1 cells (TNF-α expression; nuclear translocation of NF-κB; generation of ROS) | Prednisone | Hanáková et al. ( |
|
| TNF-α-stimulated A549 cells (IL-8 expression) | NP | Ryu et al. ( |
|
| TNF-α-stimulated A549 cells (IL-8 expression) | NP | Ryu et al. ( |
|
| TNF-α-stimulated A549 cells (IL-8 expression) | NP | Ryu et al. ( |
|
| LPS-induced THP-1 cells (TNF-α expression; nuclear translocation of NF-κB; generation of ROS) | Prednisone | Hanáková et al. ( |
aIndividual cell models, including RAW264.7 cells: murine macrophage cell line; J774.A1 cells: murine macrophage cell line; THP-1 cells: monocytic leukaemia cell line; A549 cells: human alveolar basal epithelial adenocarcinoma cell line
bIndividual enzymes and inflammatory cytokines, including COX-2: cyclooxygenase-2; MMP2: matrix metalloproteinase-2; ZFP36: zinc finger protein 36; NF-κB: nuclear factor κB; ROS: reactive oxygen species; IL-8: interleukin 8; TNF-α: pro-inflammatory cytokine
cLPS: Lipopolysaccharide
Cytotoxic activity of different Paulownia C-geranylated flavonoids against human cancer cell lines in comparison to the standard cytotoxic agents
| Compounds | Cytotoxic effecta | Positive control | References |
|---|---|---|---|
|
| WB 344 (NE)b | NP | Šmejkal et al. ( |
| THP-1 (IC50 6.6 µM) | NP | Hanáková et al. ( | |
|
| WB 344 (IC50 14.3 µM) | NP | Šmejkal et al. ( |
| MCF (EC50 < 10 µM); CEM (EC50 3.2 µM); RPMI8226 (EC50 < 10 µM); U266 (EC50 2.4 µM); HeLa (EC50 < 10 µM); BJ (EC50 5.9 µM); THP-1 (EC50 < 10 µM) | Olomoucine II, Diaziquone, Oxaliplatin, Camptothecin (Data in reference) | Šmejkal et al. ( | |
|
| MCF (EC50 < 10 µM); CEM (EC50 < 10 µM); RPMI8226 (EC50 7.1 µM); U266 (EC50 1.9 µM); HeLa (EC50 6.3 µM); BJ (EC50 7.5 µM); THP-1 (EC50 8.5 µM) | Olomoucine II, Diaziquone, Oxaliplatin, Camptothecin (Data in reference) | Šmejkal et al. ( |
|
| WB 344 (IC50 30.2 µM) | NP | Šmejkal et al. ( |
| MCF (EC50 < 10 µM); CEM (EC50 < 10 µM); RPMI8226 (EC50 7.3 µM); U266 (EC50 5.5 µM); HeLa (EC50 7.4 µM); BJ (EC50 4.7 µM); THP-1 (EC50 < 10 µM) | Olomoucine II, Diaziquone, Oxaliplatin, Camptothecin (Data in reference) | Šmejkal et al. ( | |
| THP-1 (EC50 7.1 µM) | NP | Hanáková et al. ( | |
|
| THP-1 (IC50 7.9 µM) | NP | Hanáková et al. ( |
|
| THP-1 (IC50 6.4 µM) | NP | Hanáková et al. ( |
|
| THP-1 (IC50 8.0 µM) | NP | Hanáková et al. ( |
|
| THP-1 (IC50 7.2 µM) | NP | Hanáková et al. ( |
|
| A549 (IC50 8.9 µM) | Oridonin (IC50 18.7 µM) | Gao et al. ( |
|
| A549 (IC50 23.7 µM) | Oridonin (IC50 18.7 µM) | Gao et al. ( |
|
| THP-1 (IC50 6.5 µM) | NP | Hanáková et al. ( |
|
| THP-1 (IC50 > 5 µM) | NP | Kollár et al. ( |
|
| THP-1 (IC50 6.7 µM) | NP | Hanáková et al. ( |
|
| A549 (IC50 22.1 µM) | Oridonin (IC50 18.7 µM) | Gao et al. ( |
|
| THP-1 (IC50 6.7 µM) | NP | Hanáková et al. ( |
aIndividual cell models, including WB 344: epithelioid cell line; A549: lung cancer cell line; MCF-7: breast carcinoma cell line; CEM: T-lymphoblastic leukaemia cell line; RPMI 8226 and U266: multiple myeloma cell line; HeLa: cervical cancer cell line; THP-1: monocytic leukemia cell line; BJ: fibroblast cell line
bNE: The IC50 could not be estimated because the cytotoxicity was less than 50% of that of the control
Enzymatic inhibitory effects of different Paulownia C-geranylated flavonoids in comparison to the positive controls
| Compounds | Enzymatic inhibitory effectsa (IC50, µM) | Positive control | References |
|---|---|---|---|
|
| COX-1 (3.7); COX-2 (6.0) | Ibuprofen (IC50 6.3, 4.2 µM) | Hanáková et al. ( |
| SARS-CoV PLpro (14.4) | NP | Cho et al. ( | |
| PTP1B (1.9); α-Glucosidase (30.7) | NaVO4 (IC50 32.6 µM); Voglibose (IC50 24.5 µM) | Song et al. ( | |
|
| COX-1 (1.8), COX-2 (4.2); 5-LOX (0.05) | Ibuprofen (6.3, 4.2); Zileuton (0.35) | Hanáková et al. ( |
| AChE (7.2), BChE (1.4) | Eserine (0.15, 3.7) | Cho et al. ( | |
| SARS-CoV PLpro (10.4) | NP | Cho et al. ( | |
|
| HNE (7.8) | Luteolin (12.7) | Ryu et al. ( |
| SARS-CoV PLpro (13.2) | NP | Cho et al. ( | |
| PTP1B (3.9); α-Glucosidase (18.4) | NaVO4 (32.6); Voglibose (24.5) | Song et al. ( | |
|
| COX-1 (3.3), COX-2 (10.6); 5-LOX (0.06) | Ibuprofen (6.3, 4.2); Zileuton (0.35) | Hanáková et al. ( |
|
| 5-LOX (0.38) | Zileuton (0.35) | Hanáková et al. ( |
|
| SARS-CoV PLpro (12.7) | NP | Cho et al. ( |
| PTP1B (7.8); α-Glucosidase (19.6) | NaVO4 (32.6); Voglibose (24.5) | Song et al. ( | |
|
| COX-1 (4.2), COX-2 (6.4) | Ibuprofen (6.3, 4.2) | Hanáková et al. ( |
| PTP1B (3.8); α-Glucosidase (78.9) | NaVO4 (32.6); Voglibose (24.5) | Song et al. ( | |
|
| HNE (3.3) | Luteolin (12.7) | Ryu et al. ( |
| AChE (22.9), BChE (6.4) | Eserine (0.15, 3.7) | Cho et al. ( | |
| PTP1B (5.9); α-Glucosidase (6.5) | NaVO4 (32.6); Voglibose (24.5) | Song et al. ( | |
|
| SARS-CoV PLpro (13.9) | NP | Cho et al. ( |
|
| AChE (31.9), BChE (12.7) | Eserine (0.15, 3.7) | Cho et al. ( |
| SARS-CoV PLpro (9.2) | NP | Cho et al. ( | |
| PTP1B (8.2); α-Glucosidase (25.8) | NaVO4 (32.6); Voglibose (24.5) | Song et al. ( | |
|
| AChE (48.5), BChE (11.2) | Eserine (0.15, 3.7) | Cho et al. ( |
| SARS-CoV PLpro (9.2) | NP | Cho et al. ( | |
| PTP1B (4.9); α-Glucosidase (17.8) | NaVO4 (32.6); Voglibose (24.5) | Song et al. ( | |
|
| AChE (15.6), BChE (3.8) | Eserine (0.15, 3.7) | Cho et al. ( |
| PTP1B (6.6); α-Glucosidase (2.2) | NaVO4 (32.6); Voglibose (24.5) | Song et al. ( | |
|
| HNE (6.7) | Luteolin (12.7) | Ryu et al. ( |
|
| HNE (6.3) | Luteolin (12.7) | Ryu et al. ( |
|
| HNE (2.4) | Luteolin (12.7) | Ryu et al. ( |
|
| HNE (15.4) | Luteolin (12.7) | Ryu et al. ( |
|
| HNE (13.6) | Luteolin (12.7) | Ryu et al. ( |
|
| HNE (8.4) | Luteolin (12.7) | Ryu et al. ( |
|
| SARS-CoV PLpro (6.2) | NP | Cho et al. ( |
|
| SARS-CoV PLpro (6.1) | NP | Cho et al. ( |
|
| SARS-CoV PLpro (11.6) | NP | Cho et al. ( |
|
| SARS-CoV PLpro (5.0) | NP | Cho et al. ( |
|
| 5-LOX (0.35) | Zileuton (0.35) | Hanáková et al. ( |
|
| 5-LOX (0.37) | Zileuton (0.35) | Hanáková et al. ( |
aIndividual enzyme models, including COX-1 and COX-2: cyclooxygenase-1 and 2; 5-LOX: 5-lipoxygenase; SARS-CoV PLpro: severe acute respiratory syndrome-CoV papain-like protease; PTP1B: protein tyrosine phosphatase 1B; hAChE: human acetylcholinestrase; BChE: butyrylcholinestrase; HNE: human neutrophil elastase